Cargando…

PARADIGM-HF trial: will LCZ696 change the current treatment of systolic heart failure?

Detalles Bibliográficos
Autor principal:	Kaplinsky, Edgardo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Science Press 2015
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4605940/ https://www.ncbi.nlm.nih.gov/pubmed/26512236 http://dx.doi.org/10.11909/j.issn.1671-5411.2015.05.010

Ejemplares similares

Drug therapy for patients with systolic heart failure after the PARADIGM-HF trial: in need of a new paradigm of LCZ696 implementation in clinical practice
por: Filippatos, Gerasimos, et al.
Publicado: (2015)

Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF
por: Jhund, Pardeep S., et al.
Publicado: (2015)

A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure
por: McMurray, John, et al.
Publicado: (2015)

LCZ696 ameliorates lipopolysaccharide-induced endothelial injury
por: Gao, Aihong, et al.
Publicado: (2021)

LCZ696, an angiotensin receptor neprilysin inhibitor (ARNI): clinical development in heart failure and hypertension
por: Lefkowitz, Martin P
Publicado: (2011)

The angiotensin receptor and neprilysin inhibitor, LCZ696, in heart failure: A meta-analysis of randomized controlled trials
por: Chen, Yan, et al.
Publicado: (2022)

A Meta-Analysis on the Effect and Safety of LCZ696 in the Treatment of Hypertension
por: Zheng, Li, et al.
Publicado: (2021)

LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor (ARNI): clinical development in heart failure
por: Lefkowitz, Martin P
Publicado: (2015)

Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction
por: Kobalava, Zhanna, et al.
Publicado: (2016)

Safety of the neprilysin/renin-angiotensin system inhibitor LCZ696
por: Li, Bo, et al.
Publicado: (2017)

LCZ696 ameliorates doxorubicin-induced cardiomyocyte toxicity in rats
por: Miyoshi, Toru, et al.
Publicado: (2022)

LCZ696 Ameliorates Isoproterenol-Induced Acute Heart Failure in Rats by Activating the Nrf2 Signaling Pathway
por: Hou, Min, et al.
Publicado: (2022)

DAPA-HF trial: dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure
por: Kaplinsky, Edgardo
Publicado: (2020)

LCZ696 Therapy Reduces Ventricular Tachyarrhythmia Inducibility in a Myocardial Infarction-Induced Heart Failure Rat Model
por: Chang, Po-Cheng, et al.
Publicado: (2019)

Direct actions of dapagliflozin and interactions with LCZ696 and spironolactone on cardiac fibroblasts of patients with heart failure and reduced ejection fraction
por: Ortega‐Paz, Luis, et al.
Publicado: (2022)

After having changed the treatment of heart failure with reduced ejection fraction: what are the latest evidences with sacubitril valsartan?
por: Kaplinsky, Edgardo
Publicado: (2019)

Effect and safety of LCZ696 in the treatment of hypertension: A meta-analysis of 9 RCT studies
por: Li, Qiongqiong, et al.
Publicado: (2019)

Cardioprotective Effects of LCZ696 (Sacubitril/Valsartan) After Experimental Acute Myocardial Infarction
por: Ishii, Masanobu, et al.
Publicado: (2017)

Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double‐blind, randomized comparison of two uptitration regimens
por: Senni, Michele, et al.
Publicado: (2016)

The effect of LCZ696 (sacubitril/valsartan) on amyloid‐β concentrations in cerebrospinal fluid in healthy subjects
por: Langenickel, Thomas H., et al.
Publicado: (2016)

Single therapeutic and supratherapeutic doses of sacubitril/valsartan (LCZ696) do not affect cardiac repolarization
por: Langenickel, Thomas H., et al.
Publicado: (2016)

The protective effect of LCZ696 in coxsackievirus B3‐induced acute viral myocarditis mice
por: Jing, Xu, et al.
Publicado: (2022)

LCZ696, a promising novel agent in treating hypertension (a meta-analysis of randomized controlled trials)
por: Ye, Liwen, et al.
Publicado: (2017)

The Antihypertensive Effects and Safety of LCZ696 in Patients with Hypertension: A Systemic Review and Meta-Analysis of Randomized Controlled Trials
por: Chua, Su-Kiat, et al.
Publicado: (2021)

Paradigm-HF: a Paradigm Shift in Heart Failure Treatment?
por: Correia, Luis Cláudio Lemos, et al.
Publicado: (2016)

Changing the treatment of heart failure with reduced ejection fraction: clinical use of sacubitril-valsartan combination
por: Kaplinsky, Edgardo
Publicado: (2016)

Geographic variations in the PARADIGM-HF heart failure trial
por: Kristensen, Søren Lund, et al.
Publicado: (2016)

Effect of LCZ696, a dual angiotensin receptor neprilysin inhibitor, on isoproterenol-induced cardiac hypertrophy, fibrosis, and hemodynamic change in rats
por: Miyoshi, Toru, et al.
Publicado: (2019)

Evaluation of Pharmacokinetic and Pharmacodynamic Drug–Drug Interaction of Sacubitril/Valsartan (LCZ696) and Sildenafil in Patients With Mild‐to‐Moderate Hypertension
por: Hsiao, H‐L, et al.
Publicado: (2017)

Angiotensin II receptor Neprilysin inhibitor (LCZ696) compared to Valsartan attenuates Hepatotoxicity in STZ-induced hyperglycemic rats
por: Alqahtani, Faleh, et al.
Publicado: (2020)

LCZ696 Attenuated Doxorubicin-Induced Chronic Cardiomyopathy Through the TLR2-MyD88 Complex Formation
por: Ye, Shiju, et al.
Publicado: (2021)

Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction
por: Ito, Sadayoshi, et al.
Publicado: (2015)

LCZ696 mitigates diabetic-induced nephropathy through inhibiting oxidative stress, NF-κB mediated inflammation and glomerulosclerosis in rats
por: Mohany, Mohamed, et al.
Publicado: (2020)

LCZ696 Ameliorates Oxidative Stress and Pressure Overload-Induced Pathological Cardiac Remodeling by Regulating the Sirt3/MnSOD Pathway
por: Peng, Shi, et al.
Publicado: (2020)

Lcz696 Alleviates Myocardial Fibrosis After Myocardial Infarction Through the sFRP-1/Wnt/β-Catenin Signaling Pathway
por: Liu, Jing, et al.
Publicado: (2021)

PARADIGM-HF: Have we achieved a new paradigm in the treatment of heart failure?
por: Bonow, Robert O., et al.
Publicado: (2014)

Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials
por: Wijkman, Magnus O., et al.
Publicado: (2022)

Emerging concepts in heart failure management and treatment: focus on vericiguat
por: Kaplinsky, Edgardo, et al.
Publicado: (2023)

Prevention against renal damage in rats with subtotal nephrectomy by sacubitril/valsartan (LCZ696), a dual‐acting angiotensin receptor‐neprilysin inhibitor
por: Ushijima, Kentaro, et al.
Publicado: (2017)

LCZ696, an Angiotensin Receptor-Neprilysin Inhibitor, Improves Cardiac Hypertrophy and Fibrosis and Cardiac Lymphatic Remodeling in Transverse Aortic Constriction Model Mice
por: Ge, Qing, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tmomlh3sav6qou2nr8pe1e552h